-
Waxman asks Obama to look for alternative pathway for biosimilars
NEW YORK Support for a regulatory pathway for biosimilars has grown rapidly, and even a few branded companies, such as Merck & Co. and Pfizer, have expressed interest. But Rep. Henry Waxman's, D-Calif., request that the Obama administration look for legal means to let the FDA approve biosimilars before his bill, its companion in the Senate or fellow California Democratic Rep. Anna Eshoo’s competing bill is put to a vote, is a strong signal that biogenerics are going to be a reality in American health care — and sooner rather than later.